Clinical trial • Phase I • Infectious Disease|Neurology
IM-250 for Herpes simplex virus encephalitis | Herpes simplex encephalitis
Phase I trial of IM-250 for Herpes simplex virus encephalitis | Herpes simplex encephalitis. adaptive. 30 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease|Neurology
- Trial Disease
- Herpes simplex virus encephalitis | Herpes simplex encephalitis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 05-08-2025
- First CTIS Authorization Date
- 18-11-2025
Trial design
adaptive Phase I trial across 1 site in Bulgaria.
- Adaptive
- Yes
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 30
Recruitment
- Planned Sample Size
- 30
- Recruitment Window Months
- 12
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 30
Bulgaria
- Earliest CTIS Part Ii Submission Date
- 12-08-2025
- Latest Decision Or Authorization Date
- 18-11-2025
- Processing Time Days
- 98
- Number Of Sites
- 1
- Number Of Participants
- 30
Sites
- Site Name
- Diagnostics And Consultation Center Convex Ltd.
- Department Name
- Clinical Pharmacology
- Contact Person Name
- Andrey Petrov
- Contact Person Email
- andrewpbg@yahoo.com
- Number Of Participants
- 30
Sponsor
Primary sponsor
- Full Name
- Fuics Development Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Cyprus
Investigational products
- Investigational Product Name
- IM-250
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Frequency
- Single ascending doses
Related trials
Other published trials that may interest you.